Evidence map›Paper›PMID 39601550›Full record

ArticleAntimicrobial agents and chemotherapy2025

Real-time evaluation of macozinone activity against

Anthony Vocat, Amanda Luraschi-Eggemann, Claudia Antoni, Gino Cathomen, Danuta Cichocka, Gilbert Greub, Olga Riabova, Vadim Makarov, Onya Opota, Alfonso Mendoza and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Rapid delineation ofMicrobiology spectrum · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anthony VocatResistell AG, Muttenz, Switzerland.
Amanda Luraschi-EggemannResistell AG, Muttenz, Switzerland.
Claudia AntoniInnovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland.
Gino CathomenResistell AG, Muttenz, Switzerland.
Danuta CichockaResistell AG, Muttenz, Switzerland.
Gilbert GreubInstitute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0001-9529-3317
Olga RiabovaResearch Centre of Biotechnology RAS, Leninsky Prospect, Moscow, Russia.
Vadim MakarovResearch Centre of Biotechnology RAS, Leninsky Prospect, Moscow, Russia.ORCID 0000-0001-8746-2694
Onya OpotaInstitute of Microbiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Alfonso MendozaInnovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland.
Stewart T ColeInnovative Medicines for Tuberculosis (iM4TB), Lausanne, Switzerland.ORCID 0000-0003-1400-5585
Alexander SturmResistell AG, Muttenz, Switzerland.ORCID 0000-0002-3818-0428

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel drugs and improved diagnostics for

Indexed as

Antitubercular AgentsMycobacterium tuberculosisThiazinesAlcohol OxidoreductasesBacterial ProteinsMicrobial Sensitivity TestsPiperazinesAlcohol OxidoreductasesAntitubercular AgentsBacterial ProteinsDprE1 protein, Mycobacterium tuberculosismacozinonePiperazinesThiazinesantibiotic susceptibility testDprE1 inhibitorsmacozinoneMycobacterium tuberculosisnanomotion

Identifiers

PMID39601550
PMCPMC11784433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.